AcquisitionOther
INTERCEPT PHARMACEUTICALS, INC. acquired Intercept Pharmaceuticals
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
INTERCEPT PHARMACEUTICALS, INC. -> Intercept Pharmaceuticals · $19.00
market ● Transaction price represents an 82% premium to Intercept's closing price on September 25, 2023 ● Alfasigma adds Ocaliva®, the only FDA approved second-line treatment for PBC, a progressive autoimmune disease affecting the liver, which generated re
Open source record (SEC) ↗